Boston Scientific Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024
The company estimates net sales growth for the second quarter of 2024, versus the prior year period, to be in a range of approximately 10.5% to 12.5% on a reported basis, and approximately 10% to 12% on an organic basis. Second quarter organic net sales guidance excludes the impact of foreign currency fluctuations and net sales attributable to acquisitions and divestitures for which there are less than a full period of comparable net sales. The company estimates EPS on a GAAP basis in a range of $0.35 to $0.37.